Compounded Semaglutide and Tirzepatide: Why the FDA Is Closing the Door in 2026
If you've been on a compounded version of semaglutide or tirzepatide, you've probably seen the headlines this year: the FDA is working to shut that pathway down for good. For a lot of patients, this is confusing and honestly a little scary, especially if a compounded product is what made GLP-1 therapy affordable or accessible in the first place. As an internal medicine physician who has patients on both brand-name and compounded GLP-1s, I want to walk you through what's actually changing, why regulators are worried, and what it means for your care.
What's Actually Changing
During the semaglutide and tirzepatide shortages, federal law allowed specialty "503B" compounding pharmacies to legally produce copies of these drugs to fill the gap. That legal pathway closed once the shortages officially ended: tirzepatide came off the FDA's shortage list in December 2024 and semaglutide followed in February 2025. On April 30, 2026, the FDA went a step further and proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the "503B Bulks List," the list of ingredients compounders are allowed to use even outside of a shortage.
The shortage-based legal loophole that allowed mass compounding has already closed.
The FDA's 2026 proposal would make it much harder for that loophole to reopen in the future.
The public comment period on the proposal closed June 29, 2026, and a final decision is expected to follow.
Why Regulators Are Worried: The Real Safety Data
This isn't just a turf battle over market share. The FDA's own adverse event data is what's driving the push, and as a physician, it's the part that concerns me most. As of July 2025, the FDA had received more than 1,150 adverse event reports tied to compounded semaglutide and tirzepatide, many linked to dosing errors from multidose vials where patients (or even providers) miscalculated how much to draw up.
In a number of cases, patients drew and injected 5 to 20 times their intended dose from a multidose vial, some requiring hospitalization for severe nausea, vomiting, dehydration, or pancreatitis.
FDA inspections of compounding facilities have found potency deviations (too much or too little active drug), sterility failures, and undisclosed impurities.
Some compounded products add unapproved ingredients, like vitamin B12, that research shows can chemically bond with tirzepatide to form an entirely new, untested molecule.
Why Compounding Existed in the First Place
It's worth saying plainly: compounding pharmacies filled a real need. When Ozempic, Wegovy, Mounjaro, and Zepbound were in short supply, many patients simply could not get the brand-name drug at any price, and compounded versions, imperfect as they were, kept people on therapy. Legitimate 503A compounding still has a role for patients with genuine clinical needs, such as dose forms or allergen-free formulations that aren't commercially available, that's not going away.
Compounding existed to solve a genuine, FDA-acknowledged drug shortage.
Individualized, prescription-specific compounding (503A) for documented medical needs is different from mass-produced copies of a brand drug.
The safety concerns driving this crackdown are mostly about mass-market, direct-to-consumer compounded GLP-1s, not custom formulations ordered by your doctor for a specific medical reason.
If You're Currently on a Compounded GLP-1
Please don't stop your medication abruptly or panic based on a headline, but do take this seriously and loop in your physician. There are concrete steps that make this safer while the regulatory picture settles.
Talk to your doctor before making any changes: stopping GLP-1 therapy suddenly can affect blood sugar control and trigger rapid weight regain.
Ask your pharmacy directly whether your product is 503A or 503B, how it's dosed, and what quality testing it undergoes.
Watch for warning signs of a dosing problem: severe vomiting, fainting, confusion, or unusually intense side effects, and seek care right away if they occur.
Safer, FDA-Approved Alternatives
The good news is that the FDA-approved options have expanded significantly. Beyond the familiar injectables, Wegovy, Ozempic, Zepbound, and Mounjaro, patients now have Foundayo (orforglipron), the first oral GLP-1 pill, as a new option. Manufacturer savings cards, patient assistance programs, and expanding insurance coverage have also made brand-name access more attainable than it was during the shortage years.
Ask your doctor about manufacturer savings cards and patient assistance programs: they can meaningfully lower out-of-pocket costs.
If cost or access is the barrier, say so directly: there are often more options than patients realize, including newer oral formulations.
An FDA-approved product means guaranteed dosing accuracy, tested purity, and a manufacturer standing behind the drug, protections a compounded product can't offer.
The Bottom Line
The FDA's move to close the compounding loophole isn't about limiting your access to effective weight loss and diabetes treatment, it's a response to real, documented harm from dosing errors and quality control failures. If you're on a compounded GLP-1, this is a good moment to have an honest conversation with your physician about your options, your safety, and how to transition smoothly if that's the right call for you.
This article is for general informational purposes only and does not constitute medical advice. Always consult your physician or another qualified healthcare provider before starting, stopping, or changing any medication.
Sources cited
U.S. Food and Drug Administration, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List," April 30, 2026. fda.gov
U.S. Food and Drug Administration, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." fda.gov
Pharmacy Times, "FDA Moves to Permanently Close the Door on Compounded GLP-1s," 2026. pharmacytimes.com
Renal and Urology News, "FDA: Dosing Errors, Adverse Events Reported With Compounded Semaglutide." renalandurologynews.com
Comments